Technology Networks recently spoke with Mike Sherman, Chief Executive Officer at Chimerix to learn more about the company’s oncology, biodefense and COVID-19 therapeutic efforts. Mike elaborates on the two lead candidates featured in their R&D pipeline and highlights the recent initiation of a Phase 2/3 study investigating the safety and efficacy of dociparstat sodium (DSTAT,) as a treatment […]

It’s not every day that a biotech CEO is asked by his employees to leave the office. But that was the case a few weeks ago when Obsidian Therapeutics’ chief executive Paul Wotton stopped by his company’s laboratory to pick something up and check on his staff. The incident at the laboratory, which is close to Harvard […]

Status: Cyclacel and the University said April 20 they will study fadraciclib and seliciclib as potential early treatments for the inflammatory response observed in patients with COVID-19 disease. Both candidates are designed to suppress Mcl-1 in patients with proliferative diseases, while seliciclib has also been shown to efficiently suppress IL-6 transcription, a presumptive contributor to COVID-19 […]